Galectin’s NASH Phase III Trial Will Use Surrogate Measures Of Esophageal Varices
Executive Summary
Other NASH registration trails have targeted fibrosis, but Galectin's mostly-resolved discussions with US FDA will allow the belapectin program to focus of signs and symptoms of the disease.